CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 54 enrolled
Drug / intervention
experimental group 10% mouthwash of M. sylvestris extractdrug
Likely dose
experimental group 10% mouthwash of M. sylvestris extract 150 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05138484
NCT05138484Phase 3Completed

Clinical Evaluation of a Mouthwash Containing Malva Sylvestris Extract and Its Role in Reducing Oral Biofilm and Gingival Inflammation. A Randomized, Triple Masked Clinical Trial.

Aravena, Pedro, DDS, PhD·interventional·Posted Dec 1, 2021·Updated Dec 1, 2021

In Brief

A Phase 3 clinical trial evaluating experimental group 10% mouthwash of M. sylvestris extract for Periodontal Diseases. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Background: For centuries, plants (and / or their products) were the only resource available for the prevention and treatment of many diseases. However, its indiscriminate use without phytochemical, pharmacological and toxicological knowledge is a concern for health. The Malva sylvestris (family Malvaceae and popularly known as Malva) is mentioned in the literature as an ethnopharmacological medicine with anti-inflammatory, antimicrobial, wound healing and other properties. For this reason, M. sylvestris presents empirical indications in dentistry, mainly in the treatment of periodontal diseases (gingivitis and periodontitis), which are highly prevalent worldwide. However, scientific evidence is scarce in information that supports the biological properties and clinical benefits attributed to it. Objective: The objective of this study was to evaluate the effect of a mouthwash based on Malva sylvestris in the control of gingival inflammation and dental biofilm. Methods: A randomized, three-group, triple-masked clinical trial was designed. Patients from the Center of Dental Clinics of the Austral University of Chile participated with a diagnosis of gingivitis and chronic periodontitis. They were distributed randomly in three study groups: 1. Chlorhexidine mouthwash 0.12%; 2. Mouthwash with extract of M. sylvestris and 3. Mouthwash control group. The indications and dosage were identical for all groups: rinse with 10 ml, for 1 minute, every 12 hours for 7 days. The gingival index and plaque control record were recorded at the beginning and end of the follow-up period (7 days). The results obtained between the groups were compared through normality test and group analysis (ANOVA/Mann-Whitney/Dunnet p \<0.05). Results: The pharmacological potential of M. sylvestris was determined in the reduction of the plaque control record and gingival index.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChile

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedDec 1, 2021
Enrollment StartOct 20, 2017
Primary CompletionDec 17, 2018
Study CompletionJan 14, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.6 years ago

Interventions

experimental group 10% mouthwash of M. sylvestris extractdrug

To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.